Company Summary: IGC Pharma, Inc.

Overview

• Industry Focus: Development of treatments for Alzheimer’s disease (AD) and neurodegenerative conditions, with expansion into metabolic disorders.
• Type: Clinical-stage pharmaceutical company.
• Location: Maryland, USA, with offices in Washington State, Colombia, and India.
• Established: 2005.

Business Operations

• Primary Focus: Advancing drug candidates targeting Alzheimer’s symptoms, particularly agitation and sleep disturbances.
• Long-term Goal: Create therapies that address both symptoms and disease-modifying mechanisms of AD.

Drug Pipeline & Development

• Lead Drug Candidate: IGC-AD1
  • In Phase 2 clinical trials targeting agitation in Alzheimer’s patients.
  • Shows signs of efficacy with interim data indicating significant reduction in agitation and sleep disturbances.
  • Has demonstrated safety at low doses of THC in clinical trials.
  • Involves a formulation derived from federally legal hemp with THC content within legal limits.
• Other Assets & Candidates:
  • TGR-63 (preclinical): Aiming to disrupt amyloid-beta plaque formation.
  • LMP, IGC-M3, IGC-1C, and IGC-1A: Various preclinical candidates targeting AD pathology and metabolic disorders.
• Research Techniques: Utilizes artificial intelligence (AI) and machine learning (ML) for drug discovery and early detection models.

Intellectual Property

• Patents: 12 granted patents and 31 filed patent applications globally.
• IP focus: Compositions, methods of treatment, and formulations for AD, epilepsy, pain management, eating disorders, and Tourette syndrome.

Business Strategy

• Focused on:
  • Developing differentiated therapies for high-need CNS indications.
  • Expanding IGC-AD1’s potential beyond agitation if approved.
  • Publishing scientific research to strengthen credibility.
  • Strategic capital allocation into clinical trials, R&D, and infrastructure.
• Market & Competition:
  • Significant market opportunity in AD treatment.
  • Competes with larger pharmaceutical firms and other entities developing AD therapeutics.

Financials (Fiscal Year Ended March 31, 2025)

• Revenue: Approximately $1.27 million (down 6% from previous year).
• Net Loss: Approximately $7.12 million (improved from $13 million last year).
• Employees: 70 full-time employees.
• Cash & Equivalents: About $405,000 (decreased by 66% from previous year).
• Key Funding:
  • Raised over $4.64 million via private equity and ATM offerings during FY 2025.
  • Credit facility of $12 million from O-Bank.

Customer & Market

• Number of stockholders: Approximately 46 registered shareholders of record, plus unit holders.
• Sales & Revenue Sources:
  • Over-the-counter wellness and lifestyle products (e.g., gummies, lotions, hemp extracts).
  • White label formulations for third-party branding.
• Customer Concentration: Two customers accounted for over 10% of sales.

Regulatory & Legal

• Operates under FDA and other international regulations.
• Developing drugs from hemp-derived formulations, compliant with the 2018 Farm Bill.
• Involved in legal disputes related to contractual issues in Colombia.

Employees & Management

• Workforce: 70 employees.
• Leadership & Advisors: Includes notable appointments like former Virginia Governor Terry McAuliffe as a strategic advisor.

Facilities & Properties

• Owns 40,000 sq ft in Potomac, Maryland.
• Leases 16,000 sq ft in Vancouver, Washington until September 2025.
• Owns 5 acres of land in India (classified as "Asset Held for Sale").

Summary

• IGC Pharma focuses on innovative therapies for Alzheimer’s, with a lead drug candidate currently in Phase 2 trials showing promising signs of efficacy and safety.
• The company invests heavily in R&D, AI-driven drug discovery, and intellectual property development.
• Revenue is primarily from white label and wellness products, with significant R&D and clinical trial expenses leading to net losses.
• Company is actively raising capital through equity offerings and has credit facilities to fund operations.